Abionyx Pharma SA represents values of innovation, excellence, and commitment to improving patient well-being. The company's corporate philosophy revolves around driving scientific advancements and finding breakthrough solutions in the field of healthcare. Abionyx Pharma SA focuses on research and development, utilizing cutting-edge technologies to create innovative therapies and diagnostics. By fostering collaborations with leading experts and healthcare professionals, Abionyx Pharma SA aims to transform the treatment landscape and address unmet medical needs. With a strong emphasis on delivering value to patients, the company is dedicated to providing safe and effective healthcare solutions that make a meaningful difference in people's lives.

Abionyx Pharma SA is primarily present in France, where it is headquartered. However, the company also has a presence in other European countries such as Germany, Spain, Italy, and the United Kingdom. Its reach extends beyond Europe to include countries in North America, particularly the United States. Abionyx Pharma SA is continuously expanding its global presence, with a strong focus on markets that offer growth opportunities in the pharmaceutical industry.

Abionyx Pharma SA has achieved several significant milestones over the years. The company successfully completed its Phase 1 clinical trial for its lead product, ABX-123, demonstrating its safety and tolerability. Additionally, Abionyx Pharma SA secured regulatory approval to initiate Phase 2 clinical trials, marking a major step forward in the development of ABX-123. The company also entered into strategic partnerships with leading pharmaceutical companies to advance its product pipeline and expand its market reach. Abionyx Pharma SA's achievements highlight its dedication to developing innovative therapies and position it as a key player in the pharmaceutical industry.

Abionyx Pharma SA is a pharmaceutical company specializing in the development and commercialization of innovative therapies. Founded in [year], Abionyx Pharma SA has grown to become a leading player in the pharmaceutical industry. With a focus on [specific area], the company has achieved significant milestones and breakthroughs in the treatment of various medical conditions. Its commitment to research and development, coupled with strategic partnerships, has contributed to the company's success in delivering cutting-edge medications to patients worldwide. Abionyx Pharma SA has positioned itself as a leader in the industry, continually striving to improve the quality of life for patients through its innovative solutions.

The main competitors of Abionyx Pharma SA in the market include companies such as [COMPETITOR 1], [COMPETITOR 2], and [COMPETITOR 3]. These companies, like Abionyx Pharma SA, operate in the [SPECIFIC INDUSTRY/SECTOR]. While Abionyx Pharma SA focuses on [KEY PRODUCTS/SERVICES], its competitors offer similar products/services and compete for market share. By closely monitoring the activities and strategies of its competitors, Abionyx Pharma SA can stay informed and adapt its own approach to maintain a competitive edge in the market.

Abionyx Pharma SA is primarily active in the healthcare and pharmaceutical industries.

Abionyx Pharma SA follows a business model focused on developing and commercializing innovative therapeutics. They aim to address unmet medical needs in various therapeutic areas, including rare and severe diseases. Abionyx Pharma SA achieves this by investing in research and development activities to identify and advance promising drug candidates. By leveraging their expertise and strategic collaborations, they work towards obtaining regulatory approvals and marketing authorizations for their pharmaceutical products. Abionyx Pharma SA's business model centers on delivering safe and effective treatments to improve patients' quality of life and create value for their stakeholders.

P/E-forholdet til Abionyx Pharma er −7,73.

Abionyx Pharma KUV er 8,16.

AlleAktien kvalitetsscore for Abionyx Pharma er 1/10.

forventede Abionyx Pharma omsetningen er 4,69 mill. EUR.

forventede Abionyx Pharma -gevinsten er −4,95 mill. EUR.

Abionyx Pharma SA is a biotechnology company based in France that specializes in the research and development of innovative therapeutics for rare and serious diseases. The company's business model is focused on identifying existing medical needs and addressing them through the development of new drugs. Abionyx employs a holistic approach that includes research and development of new drugs, as well as the production and marketing of high-quality pharmaceuticals. The company offers a wide range of products, ranging from medicines for the treatment of rare diseases to diagnostics and laboratory supplies. Research and development of medications is a core business of Abionyx Pharma. The company employs a variety of experts, including biologists, chemists, and clinical researchers, to develop novel pharmaceuticals. The company works closely with professionals and doctors in the medical community to identify potential improvements in disease treatment. Abionyx's goal is to bring innovative and effective drugs to market in a short period of time while maintaining high quality standards. Abionyx's product range includes therapeutics for a wide range of indications such as Amyotrophic Lateral Sclerosis, Cystic Fibrosis, Neuromuscular diseases, and Sickle Cell Anemia. Abionyx's medications are durable and pure, without toxic elements. Often, the company can fill a gap in medical science by producing medications for rare diseases. By providing therapeutics for rare diseases, the company has the opportunity to achieve a high status as a specialist in niche diseases. The corporation also addresses its marketing strategy. The company works closely with patient and family associations to advance research and meet the needs of patients. The company also utilizes industry conferences and events to showcase its products and research findings and enter into partnerships with other pharmaceutical companies or institutions. Sustainability is also an important aspect of Abionyx Pharma. The company strives for environmentally friendly production, recycles waste, limits resource use, and ensures that its activities have minimal impact on the environment. The company takes its social responsibility seriously and has initiated an integrated management and leadership program to have a positive impact on all stakeholders. Abionyx Pharma is an innovative, customer-oriented company focused on the development and marketing of therapeutics for rare and serious diseases. The company's business model is well-positioned to capitalize on the opportunities presented by the development of new drugs for niche diseases. With its wide product range, intensive research and development, and sustainability strategy, Abionyx Pharma is in a strong position to succeed in a competitive industry.

Abionyx Pharma utbetaler et dividende på 0 EUR fordelt over utdelinger i året.

Utbyttet kan for øyeblikket ikke beregnes for Abionyx Pharma eller så utdeler ikke selskapet utbytte.

ISIN-en til Abionyx Pharma er FR0012616852.

WKN for Abionyx Pharma er A14QR9.

Tikkeren til Abionyx Pharma er ABNX.PA.

I løpet av de siste 12 månedene utbetalte Abionyx Pharma et utbytte på . Dette tilsvarer en utbytteavkastning på ca. . For de neste 12 månedene vil Abionyx Pharma sannsynligvis betale et utbytte på 0 EUR.

Utdelingsrendementet til Abionyx Pharma er for øyeblikket .

Abionyx Pharma betaler utbytte kvartalsvis. Dette blir utdelt i månedene .

Abionyx Pharma betalte utbytte hvert år de siste 0 årene.

For de kommende 12 månedene forventes det utbytter på 0 EUR. Dette tilsvarer en utbytteavkastning på 0 %.

Abionyx Pharma tilordnes sektoren 'Helse'.

For å motta den siste utbyttet fra Abionyx Pharma den på 0 EUR, måtte du ha aksjen i porteføljen din før ex-datoen den .

Utbetalingen av det siste utbyttet fant sted den .

I løpet av 2023 ble det utbetalt 0 EUR i utbytte fra Abionyx Pharma.

Utdelingene fra Abionyx Pharma blir betalt ut i EUR.